SCHEMBL1889480

SCHEMBL1889480

O=C(Cc1ccncc1)Nc1ccccc1C(=O)Nc1n[nH]c2c1CN(S(=O)(=O)c1cc(F)cc(F)c1)CC2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 2/20 0.55
CDK2 P24941 5/20 0.40
CCNA2 P20248 4/20 0.40
CCNA1 P78396 4/20 0.40
AURKA O14965 2/20 0.40
CHRNB2 P17787 3/20 0.38
CHRNB4 P30926 3/20 0.38
CHRNA3 P32297 3/20 0.38
CHRNA4 P43681 3/20 0.38
EP300 Q09472 1/20 0.38
CREBBP Q92793 1/20 0.38
AKR1C3 P42330 1/20 0.37
MAPK14 Q16539 1/20 0.37
NAMPT P43490 2/20 0.37
MAPK1 P28482 2/20 0.37
ALDH1A1 P00352 1/20 0.37
CDK1 P06493 1/20 0.36
GSK3A P49840 1/20 0.36
GSK3B P49841 1/20 0.36
NTRK1 P04629 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1892895 0.86 IGF1R (0.72) IGF1RAURKANTRK1
SCHEMBL1887128 0.85 IGF1R (0.56) IGF1RCHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL1888578 0.85 NTRK1 (0.44) IGF1RCDK2CCNA2CCNA1CDK1
SCHEMBL1886671 0.82 IGF1R (0.62) IGF1RCDK2CCNA2CCNA1AURKA
SCHEMBL1886628 0.82 IGF1R (0.63) IGF1RCDK2CCNA2CCNA1AURKA
SCHEMBL2678341 0.82 IGF1R (0.63) IGF1RCDK2CCNA2CCNA1AURKA
SCHEMBL1893778 0.82 IGF1R (0.76) IGF1RCDK2CCNA2CCNA1AURKA
SCHEMBL1890035 0.82 IGF1R (0.57) IGF1RCDK2CCNA2CCNA1EP300
SCHEMBL1894789 0.81 IGF1R (0.60) IGF1RCDK2CCNA2CCNA1AURKA
SCHEMBL1887337 0.81 IGF1R (0.63) IGF1RCDK2CCNA2CCNA1AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173659-B2 Substituted pyrazolo[4,3-C]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-05-08 US disclosed
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-09-22 US disclosed
US-7947686-B2 Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-24 US disclosed
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-01-22 US disclosed
EP-1968976-A1 SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-09-17 EP disclosed
WO-2007068619-A1 SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K3, MAP3K1, MAP3K19 IGF1R 760/4885CDK2 91/4885CCNA2 1202/4885
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors MAP3K3, MAP3K1, MAP3K19 IGF1R 760/4885CDK2 91/4885CCNA2 1202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.